Advertisement
Advertisement
U.S. markets open in 7 hours 4 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Travere Therapeutics, Inc. (TVTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
20.01-0.07 (-0.35%)
At close: 04:00PM EST
19.01 -1.00 (-5.00%)
After hours: 06:15PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close20.08
Open20.33
Bid0.00 x 900
Ask0.00 x 1200
Day's Range19.69 - 20.33
52 Week Range18.70 - 31.65
Volume647,122
Avg. Volume790,735
Market Cap1.284B
Beta (5Y Monthly)0.51
PE Ratio (TTM)N/A
EPS (TTM)-3.29
Earnings DateFeb 22, 2023 - Feb 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for TVTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Travere Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 10/07/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • GlobeNewswire

    Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on November 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 173,000 shares of its common stock to 12 new employees, consisting of inducement stock options to purchase an aggregate of 90,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 83,000 shares of its common stock

  • GlobeNewswire

    Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease

    Developed in collaboration with the rare kidney disease community, RKD & Me aims to amplify the experiences of people living with rare kidney disease. SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., the IgA Nephropathy Foundation, and NephCure Kidney International today announced the launch of RKD & Me, a new public awareness campaign that spotlights the real stories of people living with rare kidney disease to amplify their unique lived experiences, educate the public,

  • GlobeNewswire

    Travere Therapeutics to Present at Upcoming Investor Conferences

    SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences: Jefferies 2022 London Healthcare ConferenceWednesday, November 16, 2022, at 4:25 p.m. GMT (11:25 a.m. ET) 5th Annual Evercore ISI HealthCONx ConferenceTuesday, November 29, 2022, at 1:25 p.m. ET Piper Sandler Healthcare ConferenceThursday, December 1, 2022, at 10:30 a.m. ET BofA Securities 2022 Biotech SMID Cap Conf

Advertisement
Advertisement